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Abstract
Resistance to Imatinib Mesylate (IM) is a major problem in Chronic Myelogenous Leukaemia management. Most of the
studies about resistance have focused on point mutations on BCR/ABL. However, other types of resistance that do not imply
mutations in BCR/ABL have been also described. In the present report we aim to study the role of several MAPK in IM
resistance not associate to BCR/ABL mutations. Therefore we used an experimental system of resistant cell lines generated
by co-culturing with IM (K562, Lama 84) as well as primary material from resistant and responder patient without BCR/ABL
mutations. Here we demonstrate that Erk5 and p38MAPK signaling pathways are not implicated in the acquired resistance
phenotype. However, Erk2, but not Erk1, is critical for the acquired resistance to IM. In fact, Bcr/Abl activates preferentially
Erk2 in transient transfection in a dose dependent fashion through the c-Abl part of the chimeric protein. Finally, we present
evidences demonstrating how constitutive activation of Erk2 is a de novo mechanism of resistance to IM. In summary our
data support the use of therapeutic approaches based on Erk2 inhibition, which could be added to the therapeutic
armamentarium to fight CML, especially when IM resistance develops secondary to Erk2 activation.
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Introduction
Chronic Myeloid Leukaemia (CML) is one of the most studied
human malignancies. The disease is originated in a hematopoietic
stem cell progenitor by a reciprocal translocation between
chromosome 9 and 22 t(9:22)(q34:11) joining the c-ABL tyrosine
kinase on chromosome 9, and the Break point Cluster Region
(BCR) on chromosome 22. This generates a chimeric protein with
deregulated activity, which plays an essential role in the
pathogenesis of the disease (for review see [1]).
Deregulation induced by Bcr/Abl protein affects the function of
several signaling pathways implicated in the malignant phenotype.
Consistent with this, alterations in most of the members of the
serine-threonine kinases Mitogen Activated Protein Kinases
(MAPKs) has been demonstrated, explaining several properties
associated to BCR/ABL transformation, including survival or drug
resistance [2–4]. A major breakthrough in CML therapy has been
the design and development of specific inhibitors for Bcr/Abl
tyrosine kinase activity. The first one, Imatinib Mesylate (IM,
Gleevec
TM, formerly known as STI-571), has been widely studied
(for review[5]). This potent and specific chemical inhibitor
interacts with the ATP binding pocket of c-Abl, blocking the
tyrosine kinase activity associated with the chimeric protein.
However, in spite of the successful clinical results obtained with
IM, a major problem is the generation of resistance. Some
resistant phenotypes to IM have been explained by point
mutations in several domains of the chimeric protein, especially
those that affect the tyrosine kinase domain [6]. This has
prompted the generation of new therapeutic agents to overcome
this type of resistance [7,8]. Futhermore, IM has also been
reported to fail to control disease progression in the absence of
BCR/ABL mutations, an aspect that remains poorly understood
[9,10]. Several mechanisms, such as the overexpression of Bcr/
Abl, increases in drug efflux transport proteins or the overexpres-
sion of other members of the Src tyrosine kinase family have been
proposed to explain the failure to respond to IM (for a review
[11]). Drug resistance can be divided in two general types: de novo,
presents in patients who are resistant to therapy from the
beginning of the treatment; and acquired resistance, that occurs
in those that develop resistance during treatment. In this sense,
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6124continuous exposure to IM allowed us to obtain an experimental
system that mimics the acquired resistance ([12–14]). Interestingly,
de novo and acquired resistance to IM in CML seem to have a
convergence point in the Bcr/Abl overexpression, which is a
common feature of the two last phases of the disease [15–17].
In this scenario, we decided to evaluate the role of several
members of the MAPKs superfamily in the acquired resistance to
IM using the above mentioned experimental system. Our results
demonstrate a critical role for Extracellular Signal-Regulated
Kinase (ERK) 2 in the acquired resistance to IM, excluding other
MAPK such as p38 and Erk5. The proposed role for Erk2 not only
applies to acquired resistance, our data demonstrate that
constitutive activation of this particular MAPK can render de novo
resistance. These results could also explain the clinical failure
observed in the advanced stages of the CML in which the high
Bcr/Abl expression level is a critical event.
Materials and Methods
Ethics Statement
The Investigation committee of the Universidad de Castilla La
Mancha approved the present research. All patients analyzed in
this study were treated at Oregon Health & Science University and
have given written informed consent for the study according to the
Declaration of Helsinki.
Chemicals and antibodies
Antibodies against the phosphorylated forms of p38MAPK,
Erk5 and Erk1/2 were purchased from Cell Signaling Technol-
ogy. Antibodies against the non-phosphorylated forms of Bcr, p38,
Erk1 (K-23) or Erk2 (C-14) were purchased from Santa Cruz
Biotechnology. Antibodies against the non phosphorylated form of
Erk5 were purchased from Cell Signaling Technology, or obtained
in our laboratory [18]. HA antibody was purchased from Babco.
Antibody against c-Abl was from BD Biosciences. Phosphotyrosine
(4G10) was from Upstate Biotech. PD98059 and SB203580 were
from Calbiochem. BIRB0796 was obtained from the University of
Dundee. IM was kindly supplied by Elisabeth Buchdunger
(Novartis-Pharma, Basel, Switzerland).
Cell Lines and Plasmids
293 T cells were maintained in 5% CO2,a t3 7 uC in DMEM
(Biowhitaker) supplemented with 10% FBS plus antibiotics
(Biowhitaker). Lama84, K562 cells and resistant derivates (a
generous gift from Dr. J. V. Melo, Institute of Medical &
Veterinary Science Adelaide, Australia) were maintained in RPMI
supplemented with 10% FBS plus antibiotics. Resistant cells to IM
were routinely maintained in the presence of 1 mM of this
inhibitor. ?32D cells harboring K-Ras wt and mutant forms have
been previously described [19]. The plasmid for constitutively
active HA tagged MEK1 was kindly supplied by Dr. R. Pulido
(CIPF, Valencia, Spain). The expression vector for BCR/ABL was
kindly supplied by Dr J. Pear (USF, California, USA). Plasmids for
Green Fluorescent Protein (GFP)-ABL and BCR have been
previously described [3,20].The plasmid for GFP-tagged PEA15
was a generous gift from Dr. H Chneiweiss (Institut National de la
Sante et de la Recherche Medicale, Paris, France). shRNA for
ERK5 and luciferase in pRetro-QSiren was kindly provided by Dr.
M. Villalba (IGMM, CNRS, Montpellier, France). ShRNA for
ERK2 and ERK1 in PLKO-PURO vector were purchased from
Sigma. We selected the best performing clone shRNA for further
analysis, as judged for functional interference with exogenous
tagged protein by western blotting.
Patient samples
Mononuclear cells (MNCs) were isolated from patient bone
marrow aspirates or peripheral blood samples by Ficoll density
gradient centrifugation. For direct immunoblots, 2 million cells
were lysed in sample buffer (75 mM Tris pH 6.8, 3% SDS, 15%
glycerol, 8% b-mercaptoethanol, 0.1% bromophenol blue) and
whole cell lysates were separated by SDS-PAGE. Patient samples
utilized in this study are wild type for BCR-ABL covering the Cap,
SH3, SH2 and kinase domains of ABL (exons 1–9), KRAS (exons 3–
5), NRAS (exons 2–5), PTPN11 (exons 3, 4, 8 and 13), KIT (entire
coding region), FLT3 (exons 14 and 20), JAK2 (exon 14), PDGFRa
(exons 12, 14 and 18) and PDGFRb (exons 11 and 17
Western blotting and immunoprecipitation assays
For ERK1/2 and p38MAPK detection, cells were collected in
lysis buffer containing 25 mM HEPES, pH 7.5, 0.3 M NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 1% Triton X-100, 0.1% SDS,
0.5% Deoxycholic Acid, 20 mM b-glycerolphosphate. For ERK5
detection, cells were collected in 100 mM HEPES, pH 7.5,
50 mM NaCl, 0,1% Triton X-100, 5 mM EDTA, 0,125M
EGTA. In both cases protease and phosphatase inhibitors
(0.2 mg/ml Leupeptin,2 mg/ml Aprotinin, 1 mM PMSF and
0.1 mM Na3VO4) were added. The indicated amounts of protein
were loaded onto 10% SDS-PAGE, transferred to nitrocellulose
filters and blotted against different proteins using specific
antibodies against the phosphorylated form or the total protein.
In the immunoprecipitation assays, extracts were precleared and
soluble fractions were incubated with the indicated antibody. After
2 hours, extracts were incubated for 45 minutes in the presence of
protein G (Gamma bind Sepharose, Pharmacia Biotech) and then
washed 3 times in the same lysis buffer. Then immunocomplexes
were resuspended in loading buffer, and loaded onto SDS-PAGE
gels. Images show a representative blot out of three experiments
with nearly identical results.
Transfections
293 T were transiently transfected by using Lipofectamine
(Invitrogen) following manufacturer’s instructions. The total
amount of DNA was normalized using an empty vector. Cells
were lysed 36 h after transfection and samples were processed for
immunoprecipitation or Western blot as previously described. In
the case of stably transfected, K562 cells, we used the same
protocol with Lipofectamine. 36 h after transfection positives
clones were selected with Puromycin (5 mg/ml) or G418 (650 mg/
ml) both purchased from Sigma.
Proliferation assays
Proliferation was evaluated by MTS method using CellTiter 96
AQ Non-Radiactive Cell Proliferation Assay (Promega) following
manufacturer’s instructions. The colorimetric reagent was added
to each well, incubated for 1–4 h at 37uC in 5%CO2 and the
absorbance values read at 490 nm. Statistical significance was
obtained by using an unpaired t test running in Graph PAD prism
program.
Immucytochemistry
K562 cells were plated onto sterile coverslips treated with
polilysine (Sigma-Aldrich). Then samples were fixed in parafor-
maldehide (4%) at 4uC for 5 minutes and incubated in PBS buffer
containing 10% normal goat serum and 0.3% Triton X-100
(blocking buffer). Samples were then incubated with pErk1/2
overnight and, after extensive wash; incubated 45 minutes with
Alexa fluor 546 conjugated anti-mouse antibodies (Molecular
ERK2 and Imatinib Resistance
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Fluorosave (Calbiochem). Positive immunoflorescence was detect-
ed in a Leica-DMRXA-photomicroscope.
Results
IM resistant cell lines display higher levels of Bcr/Abl than
parental cells, but their tyrosine kinase activity is blocked
by IM
To analyze the role of several members of the MAPK family in
the acquired resistance to IM we used two cell lines, K562 and
Lama84, and their resistant derivates generated by co-culturing
with IM [13]. First, we evaluated the action of IM on the viability
of sensitive and resistant cell lines. IM had a significantly higher
action on sensitive K562 (fig. 1A) and Lama84 cells (fig. 1B). Next,
we evaluated Bcr/Abl expression levels, that were higher in
resistant cells (fig. 1A and B), according to previous reports [12].
We evaluated the inhibition of tyrosine phosphorylation by IM in
resistant and sensitive cell lines (fig. 1A and B). As expected
resistant cell lines, considering that cells growth in the presence of
1 mM, showed no effect by the incubation with this dose of IM,
while all the cell lines tested showed a marked decrease in the
overall Tyr-phosphorylation pattern after a short exposure to IM
5 mM. Indeed, the same results were obtained in an experimental
model of murine Baf3 cells, expressing an exogenous BCR/ABL,i n
which resistant cells displayed higher levels of Bcr/Abl that is
inhibited by IM (data not shown). This set of experiments indicates
that in our experimental system resistance correlates with an
increase in Bcr/Abl expression level and also excludes mutations
in the ATP binding site.
Basal activation of Erk1/2 correlates with resistance to IM
Erk1/2 have been related to IM acquired resistance [12].
Interestingly, hyperactivation of Erk1/2 was detected in the
resistant cells lines while remained almost inactive in the sensitive
cell lines (fig. 2A). Immunofluorescence studies (fig. 2B), indicate
that active Erk1/2 was present in the nucleus of resistant cells, but
not in the IM sensitive cell counterpart. In fact, the nuclear
localization of Erk1/2 is a critical issue for IM resistance (see
Figure S1). Furthermore, the use of a specific inhibitor of the
Erk1/2 signalling pathways, induces an increase of the toxicity
associated to IM only in the resistant cells (fig. 2C), corroborating
the critical role of Erk1/2 in response to IM. In fact, similar results
were obtained in the Lama84 experimental system (Figure S2). In
an attempt to extrapolate our cell culture observation to human
primary material, we also analyzed the activation status of Erk2 in
few samples from IM resistant CML patients -with no mutation in
BCR/ABL- and IM responders. Interestingly none of the
Figure 1. IM resistant cell lines display higher levels of Bcr/Abl than parental cells. (A) Sensitive (black bars) and resistant (white bars) K562
cell lines were exposed to several concentrations of IM for 48 hours; after which viability was determined by MTS assays. The histogram represents at
least 3 independent experiments performed in triplicate cultures. Bars: mean6Standard Deviation. Right panel, K562 sensitive and resistant cell lines
were treated with IM 1 or 5 mM for 1 and 2 hours, then lysed and blotted against the indicated primary antibodies by using 100 mg of total cell
lysates. As a loading control membranes were re-probed against tubulin. (B) Same as in A for Lama84 cell lines.
doi:10.1371/journal.pone.0006124.g001
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Erk1/2 (fig. 2D and Figure S3). In contrast, and according to the
data obtained in the cell lines, the only primary resistant patient
with high Bcr/Abl levels (as determined by cytogenetic analyses)
showed marked Erk1/2 phosphorylation (fig. 2D and Figure S3).
Therefore, the data presented support the link between Erk1/2
activation, high Bcr/Abl expression level and IM resistance.
Erk2 activation, but not Erk1, provokes acquired
resistance to IM
Interestingly, in our prior observation we detected only a single
major band for Erk1/2 that was referred to as phospho-Erk1/2.
To gain further insight into the characterization of the band
detected by the anti-pErk1/2 antibody, we performed immuno-
precipitation assays in resistant cell lines, using antibodies against
active (phosphorylated) Erk1/2 and then immunocomplexes were
blotted against both MAPKs, showing a pattern consistent with
Erk2 as the use of total cell lysate from 293 T cells indicate
(fig. 3A). This apparent specific activation of Erk2 could be initially
explained by the different expression levels between both MAPKs.
However, we performed transient transfection approaches to
reach similar expression levels of Erk1 and Erk2. Interestingly,
Bcr/Abl preferentially activated Erk2 with almost no effect on
Erk1 (fig. 3B). Indeed, this effect was found to be dose dependent
(fig. 3C). Furthermore, we performed transient transfection assays
with HA-ERK2 plus BCR or c-ABL, showing that Erk2 activation
mediated by Bcr/Abl is due to the c-Abl part of the chimeric
protein (fig. 3D).
Although this set of experiments indicated a marked preference
of Bcr/Abl for Erk2 activation and a correlation with IM
resistance, they did not allow us to conclude a direct cause-effect
mechanism yet. Therefore, to demonstrate the role of this
particular MAPK we used RNAi technology to knock down the
expression of ERK2. K562 resistant cells were transfected with a
plasmid coding for an ERK2 shRNA and its control vector.
Selected mass cultures were analyzed for Erk2 expression levels
and viability in response to IM. As shown (fig. 3E), a clear decrease
in Erk2 expression was achieved in cells transfected with ERK2
shRNA, that rendered a reduction in the resistance to IM. Using
an analogous experimental setup, we also explored whether Erk1
could have a role in IM resistance. Cells were transfected with
shRNA to knock down ERK1 expression, and the selected cultures
were analyzed for expression levels and response to IM (fig. 3F). In
Figure 2. Basal activation of Erk1/2 correlates with resistance to Imatinib. (A) Sensitive and resistant K562 and Lama84 cell lines were
treated with the indicated concentrations of IM for 1 and 2 hours, lysed and analyzed by immunoblotting against active and total Erk1/2 by using
50 mg of total cell lysates. As a loading control membranes were re-probed against tubulin. (B) Immunofluorescence detection of active Erk1/2 in
K562. The image shows the most representative experiment out of three performed with nearly identical results. (C) K562 cells, sensitive (K562-S) and
resistant (K562-R), were incubated with IM 0.5 (for sensitive) or 5 mM (for resistant) in the presence (white bars) or absence (black bars) of the
indicated amounts of PD98059. Viability was referred to controls treated only with PD98059 (in the case of co- incubation with PD) or vehicle (DMSO)
in the case of IM. Treatment with PD98059 alone induces toxicity lower that 3% in resistant and sensitive cell line. The histogram represents at least 3
independent experiments performed in triplicate cultures. Bars: mean6Standard Deviation. (D) MNCs from CML patients primary resistant to IM (01,
02) and responder (03. 04) were analyzed by immunoblotting against active Erk1/2. Membrane was re-probed against total Erk2 as a loading control.
Bars: mean6Standard Deviation. * p value of 0,045.
doi:10.1371/journal.pone.0006124.g002
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affected IM action, supporting the critical role for ERK2.
In summary, the presented experiments clearly support that
acquired resistance to IM observed is due to, at least in part, the
hyper activation of the Erk2 signaling pathway that correlates with
the high levels of Bcr/Abl.
Erk2 activation mediates ‘‘de novo’’ resistance to IM
In light of our findings we next asked if Erk2 activation could
induce de novo resistance. First, we used a mutated form of H-Ras
(v-H-Ras), probably one of the best natural activators of Erk1/2
signaling pathway [21], that was retrovirally transduced onto
sensitive K562 cells. Selected pools were evaluated in terms of v-
H-Ras expression, Erk1/2 activation and IM resistance. As it is
shown (fig. 4A), expression of v-H-Ras induced a marked increase
in Erk2 activation that correlates with IM resistance. In fact, the
same results have been obtained by using mutant forms of K-Ras,
known to induces resistance to IM [19], in 32Dp210
BCR-ABL cells
as well as in a CML patient sample with a weakly activating T58I
K-Ras mutation, (Figure S4). However, overexpression of mutant
Ras proteins can affect other signalling pathways such as PI3K/
Akt [22], that has been related to IM resistance [23,24].
Therefore, to exclusively activate Erk2 without affecting other
signaling pathways, K562 sensitive cells were stably transfected
with an exogenous constitutively active MEK1. Selected pools were
evaluated in terms of Erk2 activation and IM resistance. As it is
shown (fig. 4B), cells expressing the hyperactive Mek1 showed a
marked resistance to IM. In fact this result demonstrates
Figure 3. Erk2 activation mediates acquired resistance to IM. (A) Resistant K562 and Lama84 cell lines were lysed and immunoprecipitated
against active forms of Erk1/2. Inmunocomplexes were blotted against Erk1 or Erk2 antibodies. Total cell lysated from 293 T cell line (50 mg) was used
as a control for Erk1 or Erk2. KR and LR mean K562 resistant and Lama 84 resistant respectively. (B) 293 T cells were transiently co-transfected with HA-
ERK1 or HA-ERK2 (0.5 mg), with or without BCR/ABL (4 mg) using lipofectamine. Next day cells were O/N starved. Then cells were collected in lysis
buffer, inmunoprecipitated against HA and immunocomplexes were blotted against phospho-Erk1/2 and re-probed against HA. Bcr/Abl expression
was evaluated by western blotting in total cell lysates. (C) 293 T cells were transiently transfected as in B with HA-ERK1 or HA-ERK2 (0.5 mg), plus BCR/
ABL (0, 2, 4 or 6 mg) by using lipofectamine. As a control, cells were tranfected with a plasmid coding for GFP. 36 hours after transfection cells were
collected in lysis buffer for Erk1/2 and immunoprecipitated against HA and blotted with phospho-Erk1/2 and HA. (D) 293 T cells were transiently co-
transfected with HA-ERK2 (0.5 mg), plus ABL or BCR (2 mg) using lipofectamine. 36 hours after transfection cells were collected in lysis buffer and
immunoprecipated against HA. Immunocomplexes were blotted against phospho-Erk2 and re-probed against HA. Bcr and c-Abl expression was
evaluated by Western blotting in total cell lysates. (E) K562 resistant cells were transfected with empty vector-PLKO-puro- (black bars) or shRNA
against ERK2 (white bars) were exposed to the indicated concentrations of IM, 48 hours later the viability was determined by MTS assays. The
histogram represents at least 3 independent experiments performed in triplicate cultures. Bars: mean6Standard Deviation. Upper panels, Knock
down of ERK2 in K562 resistant cells through shRNA was evaluated by Western blotting. As a loading control membranes were re-probed against
tubulin. (F) Same as in D but with ERK1shRNA. * p value of 0,045.
doi:10.1371/journal.pone.0006124.g003
ERK2 and Imatinib Resistance
PLoS ONE | www.plosone.org 5 July 2009 | Volume 4 | Issue 7 | e6124unequivocally that Erk2 activation is ‘‘per se’’ a mechanism of
resistance regardless of other molecules/pathways activated/
inhibited by Bcr/Abl or any previous exposure to IM.
Lack of p38MAPK or Erk5 involvement in acquired
resistance to IM
Two other members of the MAPK superfamily, Erk5 and
p38MAPK, have been related to IM resistance [2,25]. To evaluate
the specificity of our observation about the role of ERK2 in IM
resistance we decided to study these two MAPKs. First, we studied
the p38MAPK signaling pathway and no differences in the
activation status were detected in any of the cell lines tested,
regardless the presence/absence of IM (fig. 5A). Anyway, to
definitively discard the possible role of p38MAPK signaling
pathway we used pyridinyl imidazole SB203580, a compound
known to inhibit the two main members of this MAPK subfamily
p38a and p38b [26]. As shown in figure 5B, no effect was observed
due to the presence of the p38MAPK inhibitor. In addition,
SB203580 did not modify the response to IM of Lama 84 sensitive
and resistant cell lines (Figure S5). Furthermore, to exclude all the
p38MAPK family members we used the highly specific inhibitor of
all p38MAPKs, BIRB0976 [27] showing the same effect as
SB203580 (fig. 5C).
Regarding to Erk5 no variation in terms of amount/dual
phosphorylation was detected in any of cell lines tested regardless
the presence/absence of IM (fig. 6A). Considering that no specific
inhibitor for this particular MAPK is available, retroviral vectors
containing shRNA against ERK5 were transduced onto resistant
and sensitive cell lines (fig. 6B). A marked decrease (.50%) was
achieved in Erk5 expression levels, but no significant effect was
observed in the response to IM (fig. 6 C and D).
Figure 4. Erk2 mediates de novo resistance to IM. (A) Sensitive K562 cells were retrovirally transduced with a mutant form of H-Ras. Selected
cultures were analyzed in terms of v-H-Ras expression and Erk2 activation. As a loading control tubulin was evaluated. K562 control (black bars) and v-
H-Ras expressing cells (white bars) were exposed to the indicated concentrations of IM. 48 hours after this treatment the percentage of survival cells
was determined by MTS assay. The histogram represents at least 3 independent experiments performed in triplicate cultures. Bars: mean6Standard
Deviation. (B) Sensitive K562 cells were stably transfected with empty vector PCDNA3 (control) or PCDNA3 HA-tagged constitutively active MEK1.
Expression and functionality was tested by western blotting against HA and active Erk2 respectively. As a loading control tubulin was evaluated. K562
control (black bars), and HA-Mek1 hyperactive cells (white bars) were exposed to the indicated concentrations of IM. 48 hours after this treatment the
percentage of survival cells was determined by MTS assay. The histogram represents at least 3 independent experiments performed in triplicate
cultures. Bars: mean6Standard Deviation. ** p value,0,007, *p value,0.02.
doi:10.1371/journal.pone.0006124.g004
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these two particular MAPKs in the response to IM and support a
specific and unique role for Erk2 in our experimental system.
Discussion
Several conclusions can be obtained from the present study. We
found that not all the MAPK family members seem to be critical
mediators in the acquired resistance to IM. In this sense, several
MAPKs members have been related to IM resistance, but each
kinase has been evaluated in a different cell line. Therefore, to
avoid any variation due to the cell context, we evaluated these
MAPKs in the same experimental system in terms of IM
resistance. It is noteworthy that in our experimental model,
K562 and Lama84 cell lines, both derived from patients in blast
crisis, the resistant variants show a marked increase in Bcr/Abl
expression levels, obviously implicated in IM resistance. Interest-
ingly, it has been reported that in K562, the resistant variant did
not increase the Bcr/Abl expression levels [13]. However, other
report, as well as our data, demonstrate an increase in the Bcr/Abl
protein expression [12] in the same experimental model. This
apparent discrepancy could be explained, among several possibil-
ities, by the maintenance of cultures for long periods of time in the
presence of IM, which probably could select clones with higher
levels of Bcr/Abl expression as has been recently demonstrated
[28].
Regarding the p38MAPK signaling pathway it has been
reported to have a central role in BCR/ABL associated
transformation [29,30] as well as in the resistance to other
antitumoral agents used in CML [3,31]. Although it has been
considered as a key molecule in the therapeutic effect of IM [25],
our data indicate a lack of involvement for p38MAPK in the
response to this antitumor agent. Several differences should be
considered between our data and those from Parmar and
colleagues. First, a different experimental system was used, and
second and more important, this previous report studied the role
of this MAPK in de novo resistance. Interestingly, we did no detect
any effect by the inhibition of p38MAPK in K562 parental cells as
well as in the Lama84 parental cell line, indicating a marginal role
in de novo resistance at least in our experimental system. Supporting
our data, there are two key biochemical evidences. On the one
hand, p38MAPK is activated by Bcr [3,32], on which the effect of
IM is null; and on the other hand, it has been recently reported
that c-Abl activates p38MAPK through the stabilization of Mkk6
Figure 5. P38MAPK is not implicated in the response to IM. (A) Sensitive and resistant K562 and Lama84 cell lines were treated with indicated
concentrations of IM for 1 and 2 hours, lysed and analyzed by immunoblotting against active and total p38MAPK by using 50 mg of total cell lysates.
As a loading control membranes were re-probed against tubulin (data not shown). (B) K562-S and K562-R were incubated with the indicated amount
of IM in the presence (white bars) or absence (black bars) of SB203580 and then viability was determined 48 hours later. The histogram represents at
least 3 independent experiments performed in triplicate cultures. Bars: mean6Standard Deviation. (C) Same as in B but using BIRB0796. Viability was
referred to controls treated only with SB203580 or BIRB0796 (in the case of co-incubation with inhibitor) or vehicle (DMSO) in the case of IM alone.
Treatment with SB 203580 or BIRB0796 alone induces toxicity lower than 2% in resistant and sensitive cell line.
doi:10.1371/journal.pone.0006124.g005
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data suggest a discrete role for the p38MAPK signaling pathway in
the resistance to IM, or at least in the acquired one.
In addition, our results also discard another MAPK superfamily
member, Erk5. The stability of this particular MAPK seems to be
controlled by c-Abl and Bcr/Abl and also has been postulated to
be a critical player in terms of de novo resistance [2]. In this regard
we have been able to reproduce the control exerted by Bcr/Abl
onto Erk5 stability (data not shown), but we failed to demonstrate
a role for Erk5 in IM resistance in K562 cells. However, we cannot
fully exclude that in certain circumstances, for example increased
Erk5 expression, this kinase may contribute to IM resistance as has
been demonstrated for MEG01, KG-1 or Ku812 cells [2].
But the connection between MAPKs and CML therapy is not
restricted to Erk5 or p38MAPK. A previous report demonstrated a
critical role for Erk1/2 signaling pathway in IM response [12]. In
this sense the specificity of Erk2 in IM resistance is one of the most
important conclusions of the present report. This conclusion is
clearly inferred from several experimental data. First, Lama84 and
K562 showed a constitutive activation of Erk2 in the resistant cell
lines, while Erk1 remained almost undetectable. Furthermore, our
data obtained in transient transfection assays demonstrate the
specificity of Bcr/Abl for Erk2 activation. In fact this is the first
evidence of a specific activation of Erk2 by Bcr/Abl, excluding
Erk1, demonstrating a new differential role for these two close
MAPKs in CML. This observation, specificity for Erk2 but not for
Erk1 -although surprising- is not unique. Probably a differential
affinity of Bcr/Abl for the MAPKKs of this signaling pathway
could be a plausible explanation. In this regard it has been
previously demonstrated how Bcr/Abl activates p38MAPK
through both upstream molecules Mkk3 and Mkk6, but c-Abl
only affects Mkk6 [3,32]. This observation could be extremely
important, considering that the effect of Bcr/Abl onto Erk2 is only
mediated through c-Abl part of the chimeric protein as we have
shown. The second experimental evidence came from the specific
knock down of ERK2, but not of ERK1, which increases the IM
associated toxicity in resistant cell lines and has no effect in the
parental cell lines. And finally, constitutive activation of Erk2
renders resistance in sensitive cell lines, indicating that no other
signaling pathway is required for the IM resistance mediated
through Erk2. The specific role of Erk2 in IM resistance could be
explained, among several possibilities, by selective target for this
particular MAPK. For example, it has been reported that BCLXL
and BIM -member of the Bcl2 family- are modulated by Erk2 but
not by Erk1 [33]. Interestingly, Bim is a proapoptotic molecule
[34], critical in IM antileukemic effect [35]. Nonetheless, further
Figure 6. Lack of correlation between Erk5 signaling pathway and resistance to IM. (A) Same as in Fig. 5A but using 120 mg of total cell
lysates blotted against indicated antibodies. As a loading control membranes were re-probed against tubulin. (B) Western blot analysis against Erk5i n
K562 sensitive and resistant cell line with control plasmid or shRNA against ERK5. (C) K562 sensitive cells transfected with shRNA control (black bars)
and shRNA against ERK5 (white bars) were exposed to the indicated concentrations of IM. 48 hours after this treatment viability was determined by
MTS assay. The histogram represents at least 3 independent experiments performed in triplicate cultures. Bars: mean6Standard Deviation. (D) Same
as in C but in K562 resistant cells.
doi:10.1371/journal.pone.0006124.g006
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in IM resistance as well as the universal character of this
observation.
It has been reported that CML CD34+ derived cells display
basal Erk phosphorylation which is increased in the presence of
IM [36], but several differences should be considered between our
data and those from Chu et al. First, our data are obtained
fundamentally by using cell lines derived from blast crisis, while in
the report from Chu and co-workers the conclusions are obtained
mainly from patients in chronic phase. Second, different time of
exposure to IM has been used. In this sense there are reports that
demonstrate activation of Erk1/2 by IM after 24 hours of
treatment in K562 cells [12], while also it has been reported an
inhibitory effect in similar conditions [37]. Therefore, to avoid this
discrepancy as wells as to find specific biochemical events
unrelated to toxicity we decided to use short time incubations,
that could explain the lack of effect in Erk2 phosphorylation
observed. Finally, the presence of specific growth factor for
CD34+ cells can modulate the activation of Erk1/2 in response to
IM. In fact, it has been recently report by the same group [38],
how the presence/absence of growth factors differentially
modulate several signalling pathways, including MAPK, in
response to Nilotinib, which interestingly decrease the levels of
phosphor-Erk2 in K562 cells [39].
From the therapeutic point of view, our report supports a role
for Erk2 in the acquired and in de novo resistance to IM. For
example, regarding de novo resistance, our experimental approach
using an active H-Ras, K-Ras and constitutively active Mek1
demonstrate the critical role of Erk2. In fact, Ras activating
mutation has been related with disease progression, for H and N-
Ras protoncogenes [40], and more recently it has been reported a
critical role for K-Ras mutations in IM resistance [19]. However,
Ras genes could explain the resistance in few patients due to the
low incidence of Ras mutation detected in CML [41]. But the vast
majority of IM therapy failure -excluding those associated to
mutation in the Bcr/Abl oncoprotein [42]- occur in advanced
stage of the disease in which Bcr/Abl overexpression is a hallmark
of the disease’s progression [16,43] and could account for more
than 50% of the IM resistant cases [44]. Our data using cell lines
and primary patient samples support the correlation between Erk2
activation and Bcr/Abl levels in the generation of an IM resistant
phenotype, suggesting that the use of Erk2 signaling pathway
inhibitors -that target the Ras/Raf/ERK route- could represent a
complementary therapy in those patients with advanced stages of
CML, especially in those who are refractory to IM based therapy
[45]. Furthermore, Erk2 could also be involved in the resistance to
IM related to sphingosine kinase-1 (SphK1) as has been recently
proposed [46]. In addition, our results could probably apply to the
new generation of specific inhibitors for c-Abl, such as Dasatinib
or Nilotinib [39]. Finally, the activation of Erk2 could be a critical
issue in the pathogenesis of the disease, considering the importance
of Ras signaling pathway in BCR/ABL dependent transformation
[47,48]. In fact it has been reported how in response to Ras, Erk2
has a positive role in cell proliferation while Erk1 antagonize Erk2
activity [49]. Furthermore, a critical molecule in cellular
transformation as p21WAF has been proposed to be a selective
target of Erk2 but not for ERK1 [50]. Furthermore, regarding the
progression of the disease it has been demonstrated a critical role
for Erk1/2 signaling pathway in the blast crisis of CML through
the suppression of the normal myeloid differentiation to neutrophil
in a Bcr/Abl dose dependent fashion [51]. Therefore, the selective
activation of Erk2 by Bcr/Abl can render specific biological
properties, ranging from transformation up to IM resistance, due
to the effect on exclusive targets for this MAPK.
In summary, this work demonstrates a critical role for Erk2 in
the acquired and in de novo resistance to IM, while at least two
other members of the MAPK superfamily, Erk5 and p38MAPK,
seem to have a marginal role, if any. Our data support the use of
new therapeutic approaches based on the inhibition of Erk2
signaling pathway that will improve the current therapy of CML,
even in the advanced stage of the disease were overexpression of
Bcr/Abl is a common feature.
Supporting Information
Figure S1 Role of ERK1/2 localization
Found at: doi:10.1371/journal.pone.0006124.s001 (0.13 MB TIF)
Figure S2 Effect of PD98059 on Lama84
Found at: doi:10.1371/journal.pone.0006124.s002 (0.07 MB TIF)
Figure S3 Characteristics of patients
Found at: doi:10.1371/journal.pone.0006124.s003 (0.07 MB TIF)
Figure S4 K-ras mutations and ERK1/2 activation
Found at: doi:10.1371/journal.pone.0006124.s004 (0.11 MB TIF)
Figure S5 Effect of SB203580 on Lama 84
Found at: doi:10.1371/journal.pone.0006124.s005 (0.07 MB TIF)
Acknowledgments
We appreciate the comments and suggestions of Drs. MJ. Ruiz Hidalgo
and A. Mas. We also appreciate the technical help of Elena Garcia Gil.
Author Contributions
Conceived and designed the experiments: JCG MWD AP RSP. Performed
the experiments: CIAL AA JLCV LAG AEO LdPO IBE MAdlCM
EMGM IMG. Analyzed the data: CIAL AP RSP. Contributed reagents/
materials/analysis tools: AA MWD AP. Wrote the paper: CIAL RSP.
Performed research, obtained and discussed experimental data: CIAL
JLCV LAG AEO LdPO IBE MAdlCM EMGM IMG. Provided patients
samples and performed all the determination in human samples and
discussed experimental data: AA MWD. Helped in the design research and
edited the manuscript: AP JCG. Designed the research: RSP.
References
1. Wong S, Witte ON (2004) The BCR-ABL story: bench to bedside and back.
Annu Rev Immunol 22: 247–306.
2. Buschbeck M, Hofbauer S, Di CL, Keri G, Ullrich A (2005) Abl-kinase-sensitive
levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell
survival. EMBO Rep 6: 63–69.
3. Sanchez-Arevalo LV, Aceves Luquero CI, varez-Vallina L, Tipping AJ,
Viniegra JG, et al. (2005) Modulation of the p38 MAPK (mitogen-activated
protein kinase) pathway through Bcr/Abl: implications in the cellular response
to Ara-C. Biochem J 387: 231–238.
4. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, et al. (2008)
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/
STAT pathways to leukemia. Leukemia 22: 686–707.
5. Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as
a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640–2653.
6. O’hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations
and the unsettled problem of Bcr-AblT315I: looking into the future of
controlling drug resistance in chronic myeloid leukemia. Clin Lymphoma
Myeloma 7 Suppl 3: S120–S130.
7. Martinelli G, Soverini S, Rosti G, Baccarani M (2005) Dual tyrosine kinase
inhibitors in chronic myeloid leukemia. Leukemia 19: 1872–1879.
8. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD (2007)
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant
chronic myeloid leukaemia. Nat Rev Cancer 7: 345–356.
9. Lange T, Park B, Willis SG, Deininger MW (2005) BCR-ABL kinase domain
mutations in chronic myeloid leukemia: not quite enough to cause resistance to
imatinib therapy? Cell Cycle 4: 1761–1766.
10. Sherbenou DW, Wong MJ, Humayun A, McGreevey LS, Harrell P, et al. (2007)
Mutations of the BCR-ABL-kinase domain occur in a minority of patients
ERK2 and Imatinib Resistance
PLoS ONE | www.plosone.org 9 July 2009 | Volume 4 | Issue 7 | e6124with stable complete cytogenetic response to imatinib. Leukemia 21: 489–
493.
11. Melo JV, Chuah C (2007) Resistance to imatinib mesylate in chronic myeloid
leukaemia. Cancer Lett 249: 121–132.
12. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, et al. (2002)
Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase
kinase/mitogen-activated protein kinase inhibitors interact synergistically with
STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Cancer Res 62: 188–199.
13. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, et al. (2000)
Selection and characterization of BCR-ABL positive cell lines with differential
sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of
resistance. Blood 96: 1070–1079.
14. Weisberg E, Griffin JD (2000) Mechanism of resistance to the ABL tyrosine
kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.
Blood 95: 3498–3505.
15. Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, et al.
(2005) Bcr-Abl expression levels determine the rate of development of resistance
to imatinib mesylate in chronic myeloid leukemia. Cancer Res 65: 8912–8919.
16. Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, et al. (1995) Increase of
bcr-abl chimeric mRNA expression in tumor cells of patients with chronic
myeloid leukemia precedes disease progression. Blood 86: 2371–2378.
17. Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease
evolution in human cancer. Nat Rev Cancer 7: 441–453.
18. Esparis-Ogando A, az-Rodriguez E, Montero JC, Yuste L, Crespo P, et al.
(2002) Erk5 participates in neuregulin signal transduction and is constitutively
active in breast cancer cells overexpressing ErbB2. Mol Cell Biol 22: 270–285.
19. Agarwal A, Eide CA, Harlow A, Corbin AS, Mauro MJ, et al. (2008) An
activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
Leukemia.
20. Galan-Moya EM, Hernandez-Losa J, ceves Luquero CI, de la Cruz-
Morcillo MA, et al. (2008) c-Abl activates p38 MAPK independently of its
tyrosine kinase activity: Implications in cisplatin-based therapy. Int J Cancer
122: 289–297.
21. de Vries-Smits AM, Burgering BM, Leevers SJ, Marshall CJ, Bos JL (1992)
Involvement of p21ras in activation of extracellular signal-regulated kinase 2.
Nature 357: 602–604.
22. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ,
Waterfield MD, Downward J (1994) Phosphatidylinositol-3-OH kinase as a
direct target of Ras. Nature 370: 527–532.
23. Burchert A, Wang Y, Cai D, von BN, Paschka P, et al. (2005) Compensatory
PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Leukemia 19: 1774–1782.
24. Montiel-Duarte C, Cordeu L, Agirre X, Roman-Gomez J, Jimenez-Velasco A,
et al. (2007) Resistance to Imatinib Mesylate-induced apoptosis in acute
lymphoblastic leukemia is associated with PTEN down-regulation due to
promoter hypermethylation. Leuk Res.
25. Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, et al. (2004) Role of
the p38 mitogen-activated protein kinase pathway in the generation of the effects
of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem 279:
25345–25352.
26. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, et al. (1995)
SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated
by cellular stresses and interleukin-1. FEBS Lett 364: 229–233.
27. Kuma Y, Sabio G, Bain J, Shpiro N, Marquez R, Cuenda A (2005) BIRB796
inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem 280:
19472–19479.
28. Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T (2008) Overcoming
imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and
Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-
ABL gene amplification. Int J Cancer 122: 2621–2627.
29. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, et al. (2006) A common
signaling cascade may underlie ‘‘addiction’’ to the Src, BCR-ABL, and EGF
receptor oncogenes. Cancer Cell 10: 425–435.
30. Wong S, McLaughlin J, Cheng D, Witte ON (2003) Cell context-specific effects
of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood 101:
4088–4097.
31. Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, et al. (2001) The p38
MAPK pathway mediates the growth inhibitory effects of interferon-alpha in
BCR-ABL-expressing cells. J Biol Chem 276: 28570–28577.
32. Korus M, Mahon GM, Cheng L, Whitehead IP (2002) p38 MAPK-mediated
activation of NF-kappaB by the RhoGEF domain of Bcr. Oncogene 21:
4601–4612.
33. D’Souza WN, Chang CF, Fischer AM, Li M, Hedrick SM (2008) The Erk2
MAPK regulates CD8 T cell proliferation and survival. J Immunol 181:
7617–7629.
34. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ (2003) Activation of the
ERK1/2 signaling pathway promotes phosphorylation and proteasome-
dependent degradation of the BH3-only protein, Bim. J Biol Chem 278:
18811–18816.
35. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, et al. (2006) Bim and
Bad mediate imatinib-induced killing of Bcr/Abl+leukemic cells, and resistance
due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 103:
14907–14912.
36. Chu S, Holtz M, Gupta M, Bhatia R (2004) BCR/ABL kinase inhibition by
imatinib mesylate enhances MAP kinase activity in chronic myelogenous
leukemia CD34+ cells. Blood 103: 3167–3174.
37. Dan S, Naito M, Tsuruo T (1998) Selective induction of apoptosis in
Philadelphia chromosome-positive chronic myelogenous leukemia cells by an
inhibitor of. Cell Death Differ 5: 710–715.
38. Konig H, Holtz M, Modi H, Manley P, Holyoake TL, et al. (2008) Enhanced
BCR-ABL kinase inhibition does not result in increased inhibition of
downstream signaling pathways or increased growth suppression in CML
progenitors. Leukemia 22: 748–755.
39. Nguyen TK, Rahmani M, Harada H, Dent P, Grant S (2007) MEK1/2
inhibitors sensitize Bcr/Abl+human leukemia cells to the dual Abl/Src inhibitor
BMS-354/825. Blood 109: 4006–4015.
40. Liu E, Hjelle B, Bishop JM (1988) Transforming genes in chronic myelogenous
leukemia. Proc Natl Acad Sci U S A 85: 1952–1956.
41. Garicochea B, Giorgi R, Odone VF, Dorlhiac-Llacer PE, Bendit I (1998)
Mutational analysis of N-RAS and GAP-related domain of the neurofibroma-
tosis type 1 gene in chronic myelogenous leukemia. Leuk Res 22: 1003–1007.
42. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical
resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or
amplification. Science 293: 876–880.
43. Barnes DJ, Schultheis B, Adedeji S, Melo JV (2005) Dose-dependent effects of
Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
Oncogene 24: 6432–6440.
44. Lahaye T, Riehm B, Berger U, Paschka P, Muller MC, et al. (2005) Response
and resistance in 300 patients with BCR-ABL-positive leukemias treated with
imatinib in a single center: a 4.5-year follow-up. Cancer 103: 1659–1669.
45. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, et al. (2008)
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK,
PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia
therapy. Leukemia 22: 708–722.
46. Bonhoure E, Lauret A, Barnes DJ, Martin C, Malavaud B, et al. (2008)
Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in
chronic myeloid leukemia cells. Leukemia 22: 971–979.
47. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, et al. (2002) Critical
role for Gab2 in transformation by BCR/ABL. Cancer Cell 1: 479–492.
48. Sonoyama J, Matsumura I, Ezoe S, Satoh Y, Zhang X, et al. (2002) Functional
cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required
for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem 277:
8076–8082.
49. Vantaggiato C, Formentini I, Bondanza A, Bonini C, Naldini L, et al. (2006)
ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell
signaling differentially. J Biol 5: 14.
50. Hwang CY, Lee C, Kwon KS (2009) ERK2-dependent phosphorylation induces
cytoplasmic localization and degradation of p21Cip1. Mol Cell Biol.
51. Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, et al.
(2007) High levels of the BCR/ABL oncoprotein are required for the MAPK-
hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentia-
tion. Blood 110: 994–1003.
ERK2 and Imatinib Resistance
PLoS ONE | www.plosone.org 10 July 2009 | Volume 4 | Issue 7 | e6124